TrumpRx is a federal initiative scheduled to launch in 2026. The program aims to lower prescription drug costs by enabling direct-to-consumer (DTC) purchases from pharmaceutical manufacturers at discounted cash prices. This marks a significant shift in how Americans traditionally access brand name medications.

 Key Features of TrumpRx

• A government-run portal, TrumpRx.gov, will connect users to manufacturer DTC websites.
• Discounts will apply to cash-paying customers, and no insurance is required.
• Most-Favored-Nation (MFN) pricing will apply, aligning U.S. drug prices with the lowest prices in other developed countries.
• Initial partners include Pfizer and AstraZeneca, offering discounts of up to 85% on select medications.
• TrumpRx is not a pharmacy; it does not sell or ship drugs directly but instead serves as a referral platform.

Limitations of TrumpRx

• Insured patients may not benefit, as insurance copays can be lower than TrumpRx’s cash prices.
• Out-of-pocket payments through TrumpRx typically do not count toward insurance deductibles unless plans are modified. For patients with high-deductible health plans, this may create uncertainty about whether to use their benefits or pay out of pocket.
• There will be limited drugs available at launch, with availability restricted to products from a small group of participating manufacturers.

The Broader DTC Movement

TrumpRx is part of a growing trend toward simplifying medication access and reducing costs by bypassing traditional intermediaries like pharmacy benefit managers (PBMs). The use of MFN pricing and a streamlined referral model has drawn attention across the healthcare landscape. In response, pharmaceutical manufacturers, through their trade association PhRMA, are developing an alternative portal called America’s Medicines, which will also offer discounted cash prices directly to consumers. Several vendors are actively supporting manufacturers in launching DTC platforms, with notable examples including GoodRx, Blink Health, PHIL Direct, and AssistRx. We expect that DTC models will continue to proliferate in the coming year.

How will the DTC trend impact patients? Will existing stakeholders like PBMs, health plans, and pharmacies participate or benefit from this trend?